Table 2.

CMC of APLs and CAC of pro-APLs as measured using a fluorescent probe technique.

Compound	CAC (μM)	Compound	CAC (μM)	Compound	CAC (μM)
Miltefosine	11.2 ± 2.3	Perifosine	4.4 ± 1.7	Erufosine	1.6 ± 0.5
M12	1.1 ± 0.6	P12	1.2 ± 0.4	E12	0.7 ± 0.3
ME12	4.3 ± 2.5	PE12	2.9 ± 1.0	EE12	0.6 ± 0.2
M${}_{{\text{E}}^{\prime }12}$	1.3 ± 0.7	P${}_{{\text{E}}^{\prime }12}$	2.3 ± 1.4	E${}_{{\text{E}}^{\prime }12}$	1.1 ± 0.7
MC12	4.1 ± 2.5	PC12	4.5 ± 1.6	EC12	1.2 ± 0.2
M${}_{{\text{C}}^{\prime }12}$	2.0 ± 0.7	P${}_{{\text{C}}^{\prime }12}$	3.3 ± 0.7	E${}_{{\text{C}}^{\prime }12}$	0.9 ± 0.2
MC18:1	0.9 ± 0.4	PC18:1	2.3 ± 1.0	EC18:1	0.8 ± 0.4

Data for erufosine and erufosine prodrugs are reported from the literature (Gaillard et al., 2019).